Interleukin Kineret

Recombinant human DL-1 receptor antagonist (Anakinra, Kineret ) blocks the biological activity of interleukin-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. Thereby it reduces the pro-inflammatory activities of IL-1 including cartilage destiuction and bone resorption. Side effects include an increased risk of infections and neutropenia. 

The bacterium Escherichia coli is preferred for the production of small, aglycosy-lated proteins like Insulin, Proleukin (interleukin-2), Kineret (interleukin-1 recep-... 

Anakinra (Kineret) blocks the effects of interleukin-1 on joint tissues. Like TNF-a, interleukin-1 is a cytokine that promotes inflammation and joint destruction in rheumatoid arthritis.23,36 By blocking interleukin-1 receptors on joint tissues, anakinra prevents the destructive events mediated by this cytokine. This drug appears to be moderately effective in limiting the progression of rheumatoid arthritis, and it is generally well tolerated.36 Hence, anakinra is another option that can be used alone or in combination with other DMARDs such as methotrexate.23... 

Kineret (a recombinant form of a naturally occurring protein that regulates interleukin-1) Amgen... 

Anakinra interleukin-1 receptor antagonist IL-1 Ra (Kineret) 17.3 - 4-6 SC (0.95) Rheumatoid arthritis ... 

The interleukin-l-receptor-antagonist Anakinra (Kineret ) with its sequence of 153 amino acids was patented in 1989 by the company Synergen, and later developed to the market by Amgen (Fig. 5.92). It is produced using recombinant Escherichia coli strains, and is applied as a combination product for the treatment of severe rheumatoid arthritis. [209]... 

---